“…MitraClip (Abbott Vascular, Santa Clara, CA, USA) implantation is currently the most commonly utilised transcatheter therapy for severe MR. Clinical trials show that, although MitraClip implantation is relatively safe, an effective and durable outcome is frequently not achieved [15][16][17][18] . Transcatheter mitral valve implantation (TMVI) is a novel approach that may, theoretically, enable a more effective reduction in MR severity [19][20][21][22] . A significant concern is that a transcatheter valve cannot be implanted after a MitraClip has been deployed and released.…”